[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-331849-105":59,"doc-detail-331849-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","genomic-hallmarks-and-therapeutic-targets-of-ribosome-biogenesis-in-cancer","Genomic hallmarks and therapeutic targets of ribosome biogenesis in cancer","","Hyperactive ribosome biogenesis (RiboSis) drives uncontrolled cell proliferation, yet the genomic hallmarks and actionable therapeutic targets of RiboSis across cancers remain unclear, and tools to quantify RiboSis activity are limited. An in silico method scores RiboSis activity from individual transcriptome profiles using TCGA/GTEx bulk RNA-seq and extensive single-cell datasets across 13 cancer types. RiboSis activity is elevated in malignant cells, associates with severe outcomes, and shows copy number variation as the predominant somatic alteration in RiboSis genes. The study identifies 128 RiboSis genes as potential therapeutic targets, links activity with TP53 mutations, and predicts 23 compounds aligned with RiboSis gene expression signatures, supporting RiboSis-based anti-tumor therapy.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/genomic-hallmarks-and-therapeutic-targets-of-ribosome-biogenesis-in-cancer/331849/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/genomic-hallmarks-and-therapeutic-targets-of-ribosome-biogenesis-in-cancer/331849.png","ImageObject",300,407,{"name":92,"@type":93},"Himbo","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-12","2026-09-21",true,{"@type":102,"interactionType":103,"userInteractionCount":39},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What method does the study use to quantify ribosome biogenesis activity?","Question",{"text":112,"@type":113},"It establishes an in silico approach that scores RiboSis activity using individual transcriptome data, validated with RNA-seq from TCGA/GTEx and large-scale single-cell expression profiles.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"What genomic hallmark of RiboSis alterations is most prominent in cancer?",{"text":117,"@type":113},"The study reports that the predominant somatic alteration in RiboSis genes is copy number variation.",{"name":119,"@type":110,"acceptedAnswer":120},"How is ribosome biogenesis activity connected to patient outcomes and TP53?",{"text":121,"@type":113},"High RiboSis activity is associated with severe outcomes, and the activity is linked to TP53 mutations; hyperactive RiboSis predicts poor outcomes in lung cancer patients lacking TP53 mutations.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},331849,1790218138,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":39,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":4},687197100911,"https://ap-avatar.wpscdn.com/avatar/a000239b6f1da00475?x-image-process=image/resize,m_fixed,w_180,h_180&k=1785132997149421697","Briefings in Bioinformatics, 2024, 25(2), 1–13  \n[https://doi.org/10.1093/bib/bbae023](https://doi.org/10.1093/bib/bbae023)  \nCase Study  \nGenomic hallmarks and therapeutic targets of ribosome biogenesis in cancer  \nYue Zang†, Xia Ran†, Jie Yuan, Hao Wu, Youya Wang, He Li, Huajing Teng and Zhongsheng Sun   \nCorresponding authors. Zhongsheng Sun, HIM-BGI Omics Center, Hangzhou Institute of Medicine (HIM), Chinese Academy of Sciences, Hangzhou, China. Tel.: +86-571-88122266; E-mail: [sunzs@biols.ac.cn](sunzs@biols.ac.cn); Huajing Teng, Department of Radiation Oncology, Peking University Cancer Hospital and Institute, Beijing  \n100142, China. Tel.: +86-10-88196505; [E-mail: hjteng@bjmu.edu.cn](E-mail: hjteng@bjmu.edu.cn)[ ](E-mail: hjteng@bjmu.edu.cn)†Yue Zang and Xia Ran contributed equally to this work.  \nAbstract  \nHyperactive ribosome biogenesis (RiboSis) fuels unrestricted cell proliferation, whereas genomic hallmarks and therapeutic targets of RiboSis in cancers remain elusive, and efficient approaches to quantify RiboSis activity are still limited. Here, we have established an in silico approach to conveniently score RiboSis activity based on individual transcriptome data. By employing this novel approach and RNA-seq data of 14 645 samples from TCGA/GTEx dataset and 917 294 single-cell expression profiles across 13 cancer types, we observed the elevated activity of RiboSis in malignant cells of various human cancers, and high risk of severe outcomes in patients with high RiboSis activity. Our mining of pan-cancer multi-omics data characterized numerous molecular alterations of RiboSis, and unveiled the predominant somatic alteration in RiboSis genes was copy number variation. A total of 128 RiboSis genes, including EXOSC4, BOP1, RPLP0P6 and UTP23, were identified as potential therapeutic targets. Interestingly, we observed that the activity of RiboSis was associated with TP53 mutations, and hyperactive RiboSis was associated with poor outcomes in lung cancer patients without TP53 mutations, highlighting the importance of considering TP53 mutations during therapy by impairing RiboSis. Moreover, we predicted 23 compounds, including methotrexate and CX-5461, associated with the expression signature of RiboSis genes. The current study generates a comprehensive blueprint of molecular alterations in RiboSis genes across cancers, which provides a valuable resource for RiboSis-based anti-tumor therapy.  \nKeywords: ribosome biogenesis; pan-cancer multi-omics; therapeutic target; drug response; impaired ribosome biogenesis checkpoint  \nINTRODUCTION  \nRibosome biogenesis (RiboSis) is a complex process that generates ribosomes required for protein synthesis in the growth and proliferation of cells [1–3] . It is a tightly coordinated process that involves three RNA polymerases, approximately 80 ribosomal proteins, and approximately 200 non-ribosomal trans-acting factors [4 , 5] . RiboSis includes rRNA transcription, rRNA cleavage, rRNA modification, ribosome assembly and export of ribosomal pre-particles [6] . In malignant cells, the genes involved in each substep of RiboSis undergo somatic alterations, resulting in ribosomopathies and an increased risk of carcinogenesis [7 , 8] . The concept that ‘ribosomes translate cancer’ has gained increasing recognition [9 , 10] . Thus, understanding the contribution of these alterations to pathogenesis will allow for unveiling novel and targetable vulnerabilities in cancer. Owing to large-scale and  \nmulti-dimensional open-access data, there are numerous pancancer studies relevant to gene signatures [11–16] . However, a systematic analysis of genes involved in RiboSis in human cancers has been lacking.  \nRiboSis initiates in the nucleolus and terminates in the cytoplasm [7] . Nucleolar size and density are highly dynamic and can be adjusted according to the demands of protein synthesis. Increasing evidence has underscored hyperactive RiboSis fuels unrestricted cell growth and proliferation, and ","cbCairzoNBdr5Um0","https://ap.wps.com/l/cbCairzoNBdr5Um0","pdf",3213426,13,"English","# Abstract\n# Introduction\n## RiboSis process and dysregulation in cancer\n## Nucleolar markers and proliferative activity\n# Author Background","[{\"question\":\"What method does the study use to quantify ribosome biogenesis activity?\",\"answer\":\"It establishes an in silico approach that scores RiboSis activity using individual transcriptome data, validated with RNA-seq from TCGA/GTEx and large-scale single-cell expression profiles.\"},{\"question\":\"What genomic hallmark of RiboSis alterations is most prominent in cancer?\",\"answer\":\"The study reports that the predominant somatic alteration in RiboSis genes is copy number variation.\"},{\"question\":\"How is ribosome biogenesis activity connected to patient outcomes and TP53?\",\"answer\":\"High RiboSis activity is associated with severe outcomes, and the activity is linked to TP53 mutations; hyperactive RiboSis predicts poor outcomes in lung cancer patients lacking TP53 mutations.\"}]","Genomic hallmarks and therapeutic targets of ribosome biogenesis in cancer | PDF",1789995483,33]